Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE trial.

In a phase 2 study, neoadjuvant nivolumab and ipilimumab followed by surgery and adjuvant nivolumab was found to be a feasible treatment option with a high pathological complete response rate in patients with gastric or gastroesophageal junction cancer.

At the 2023 Great Debates & Updates in Gastrointestinal Malignancies in Chicago, regional co-chair Sonia Kupfer, MD, discussed the significant part that genetics play when treating patients with gastrointestinal cancers.